Approved Hospital Formulary
Add Formweb to your mobile device
Approved Hospital Formulary
Search results for:
zoledronic acid
zoledronic acid
- Restricted Reclast --> Restricted to Outpatient Medical.
- Restricted Zometa --> Restricted to use by: oncology, nephrology, rheumatology, endocrinology. Hospitalists limited to treatment of hypercalcemia of malignancy using the Powerplan
- Therapeutic Interchange Bisphosphonate Formulary
- Therapeutic Interchange Miscellaneous Program Formulary
Last updated: Sep. 18, 2024
- HAZ-MED: Group 3
ORDERED FORMULATION
THERAPEUTIC INTERCHANGE
pamidronate (Aredia)
zoledronic acid (Zometa)
Reclast medication guide
Reclast is formulary, restricted to the Outpatient Medical Department ONLY. Any order for an inpatient should be deferred to the outpatient setting.
ADULTS: 4 mg is the usual dose for zoledronic acid; The 3 mg, 3.3 mg, and 3.5 mg doses are for renal adjustments (not automatic). For HYPERCALCEMIA of MALIGNANCY use the 4 mg dose regardless of renal function
For HYPERCALCEMIA of MALIGNANCY, ordering through the HOSP ADULT Hypercalcemia of Malignancy Orders Powerplan is recommended. Use of the Powerplan is required for hospitalists to order zoledronic acid
Pamidronate is restricted to "no substitution" orders, otherwise interchange to zoledronic acid (Zometa) at a dose ratio of pamidronate 90 mg = Zoledronic acid 4 mg.
Reviewed: September 25, 2007 (Reclast) and August 27, 2013 and December 17, 2013 (Zometa interchange), October 22, 2019